Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.71 |
| ▸ | HTR1A | P08908 | 3/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | ACHE | P22303 | 1/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
| ▸ | DRD3 | P35462 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terflavoxate SCHEMBL29385282 | 1.00 | LMNA (0.71) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Terflavoxate SCHEMBL5944360 | 0.99 | LMNA (0.70) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| SCHEMBL8876605 | 0.86 | LMNA (0.71) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| SCHEMBL10959014 | 0.86 | LMNA (0.58) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL8874296 | 0.86 | LMNA (0.70) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL29421720 | 0.83 | LMNA (1.00) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL25801 | 0.83 | LMNA (1.00) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL124540 | 0.82 | LMNA (0.98) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL29395220 | 0.82 | LMNA (0.98) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL1650335 | 0.81 | LMNA (0.96) | LMNAHTR1AADRA1AKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-5770221-A | HIGH AND LOW MOLECULAR WEIGHT POLYISOBUTYLENE | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1998-06-23 | — | — | US | claimed |
| EP-0072620-B1 | 3-METHYLFLAVONE-8-CARBOXYLIC ACID ESTERS | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1985-12-04 | — | — | EP | claimed |
| US-4550115-A | ANTISPASMODIC, CALCIUM BLOCKER, ANESTHETIC, AND ANTINFLAMMATORY AG | RECORDATI S.A., CHEMICAL & PHARMACEUTICAL COMPANY (CH) | 1985-10-29 | — | — | US | claimed |
| EP-0072620-A1 | 3-Methylflavone-8-carboxylic acid esters | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1983-02-23 | — | — | EP | claimed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| EP-0558245-A1 | Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1993-09-01 | — | — | EP | disclosed |
| EP-0072620-B1 | 3-METHYLFLAVONE-8-CARBOXYLIC ACID ESTERS | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1985-12-04 | — | — | EP | disclosed |
| US-4550115-A | ANTISPASMODIC, CALCIUM BLOCKER, ANESTHETIC, AND ANTINFLAMMATORY AG | RECORDATI S.A., CHEMICAL & PHARMACEUTICAL COMPANY (CH) | 1985-10-29 | — | — | US | disclosed |
| EP-0072620-A1 | 3-Methylflavone-8-carboxylic acid esters | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1983-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | LMNA 2584/4885HTR1A 1254/4885ADRA1A 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.